Literature DB >> 21603549

Myeloma therapy-a new paradigm.

Archie W Brown1.   

Abstract

Entities:  

Keywords:  Bortezomib; lenalidomide; multiple myeloma; myeloma therapy; thalidomide

Year:  2008        PMID： 21603549      PMCID： PMC3096420     

Source DB:  PubMed          Journal:  Ochsner J        ISSN： 1524-5012


× No keyword cloud information.
  4 in total

1.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Authors:  S Vincent Rajkumar; Suzanne R Hayman; Martha Q Lacy; Angela Dispenzieri; Susan M Geyer; Brian Kabat; Steven R Zeldenrust; Shaji Kumar; Philip R Greipp; Rafael Fonseca; John A Lust; Stephen J Russell; Robert A Kyle; Thomas E Witzig; Morie A Gertz
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

2.  Lenalidomide--the phoenix rises.

Authors:  Alan F List
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

3.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Authors:  Donna M Weber; Christine Chen; Ruben Niesvizky; Michael Wang; Andrew Belch; Edward A Stadtmauer; David Siegel; Ivan Borrello; S Vincent Rajkumar; Asher Alban Chanan-Khan; Sagar Lonial; Zhinuan Yu; John Patin; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

4.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Meletios Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.